hemophilia B

Groundbreaking gene therapies in store for hemophiliaTreatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
New hemophilia B gene therapy appears effectiveA recent trial showed that a single intravenous infusion of a vector expressing a high specific-activity factor IX gene safely produces a sustained, effective level of factor IX coagulant activity in patients with hemophilia B.
6 facts about the new hemophilia B drugFDA recently approved Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] for the treatment of hemophilia B. Here are the top 6 facts to know about Idelvion.
FDA drug approvals-September 2014FDA actions in brief, fast-track designations,priority review, orphan drug designations
FDA Drug Approvals: April 2014FDA actions in brief, fast-track designation, orphan drug designation, first-time generic approvals
FDA approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia BFDA has approved Coagulation Factor IX (Recombinant), Fc Fusion Protein (Alprolix, Biogen Idec), for use in adults and children who have hemophilia B; it also granted the product orphan-drug designation. Alprolix is the first hemophilia B treatment designed for less frequent injections when used to prevent or reduce bleeding frequency.